Over the past 20 years, there has been an explosion of knowledge regarding the basic science of wound healing and a trend toward more evidence-based medicine. Advanced wound care technologies that have been developed include tissue-engineered skin replacement/substitutes, active wound repair modulators, advanced wound closure products, and advanced wound dressings.
This dynamic new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. market for advanced wound care products. Product areas covered by the scope of this report include tissue-engineered skin replacements and substitutes
(e.g., epidermal equivalents, dermal equivalents, and multilayer equivalents), active wound repair modulators (e.g., growth factors, gene therapy agents, stem cells, antibiotics/anti-infectives, hormones, matrix metalloproteinase enzyme inhibitors, and neuropeptides), advanced wound closure products
(e.g., surgical sealants and glues, energy-based wound closure products, automated suturing devices, and negative pressure wound therapy products), and advanced wound dressings (e.g., alginate, film, foam, hydrocolloid, hydrogel, wound contact layer, and antimicrobial dressings).
During the forecast period covered by this report, the combined U.S. market for advanced wound care products is projected to increase from $3.7 billion in 2014 to $4.7 billion in the year 2019.
Advanced wound closure products account for more than 60% of sales, followed by advanced wound dressings with 24%, tissue-engineered skin replacements/substitutes with 13%, and active wound repair modulators with the remaining 3%.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.